Author: Customer Service

Not for distribution to U.S. newswire services or dissemination in the United States TORONTO, May 10, 2026 (GLOBE NEWSWIRE) — Galantas Gold Corporation (TSX-V & AIM: GAL; OTCQB: GALKF) (“Galantas” or the “Company”) is pleased to announce that it intends to raise up to $85 million (the “Offering”) pursuant to a brokered private placement of up to 154,546,000 units of Galantas (each, a “Unit”), on a “best efforts” agency basis, at a price of $0.55 per Unit (the “Issue Price”). Canaccord Genuity Corp. will act as sole bookrunner and lead agent (the “Agent”), in connection with the Offering. Each Unit will be comprised of one common share of the Company (a “Galantas Share”) and one-half of one Galantas Share purchase warrant (a “Warrant”). Each whole Warrant will entitle the holder thereof to purchase one Galantas Share for $0.80...

Final Purchase Price is NIS 559.8 Million Tel-Aviv, Israel, May 10, 2026 (GLOBE NEWSWIRE) —  Ellomay Capital Ltd. (NYSE American; TASE: ELLO) (“Ellomay” or the “Company”), a renewable energy and power generator and developer of renewable energy and power projects in Europe, USA and Israel, today announced the consummation of the sale of its holdings (50%) in Ellomay Luzon Energy Infrastructures Ltd. (“Ellomay Luzon Energy”) to the Amos Luzon Development and Energy Group Ltd. (the “Luzon Group”). Ellomay Luzon Energy’s main asset is its holding of 33.75% of Dorad Energy Ltd. (“Dorad”). The consideration was based on a Dorad valuation of NIS 4.4 billion, i.e. a valuation of NIS 742.5 million for the Company’s indirect holdings in Dorad, net of 50% of Ellomay Luzon Energy’s net debt (outstanding bank loans minus cash and cash equivalents)...

MoonLake conducted a positive final pre-BLA (Biologics License Application) meeting with the U.S. Food and Drug Administration (FDA), where MoonLake and the FDA aligned on submission plans and the label strategy for sonelokimab (SLK) in hidradenitis suppurativa (HS) This included the acceptability of MIRA trial data to establish substantial evidence of effectiveness (SEE), full inclusion of the VELA-TEEN trial data for a label including patients aged 12 years and above, and the strategy for inclusion of safety data across the MIRA and VELA trials – this aligns with the scenario presented at the Investor Day on February 23, 2026 The proposed label in HS is therefore expected to include the MIRA trial’s ~43% HiSCR75 response and the ~29 percentage point delta-to-placebo at week 12, which are the highest values observed across any adequate...

SYDNEY, May 09, 2026 (GLOBE NEWSWIRE) — As Australia accelerates its transition to cleaner, smarter energy, Sigenergy made a powerful statement at Smart Energy Conference & Exhibition 2026, presenting one of the industry’s most comprehensive integrated energy portfolios at the International Convention Centre, Sydney. Over two days at Australia’s leading renewable energy event, Sigenergy engaged residential, commercial, and utility stakeholders across its expanding smart energy ecosystem, combining proven technology with a growing local service capability tailored to the Australian market. Visitors explored Sigenergy’s residential lineup, including a preview of SigenStor Neo, the company’s next-generation all-in-one residential energy system that integrates the inverter, battery, PCS, EMS, and gateway into a single unit.A...

GUADALAJARA, Mexico, May 09, 2026 (GLOBE NEWSWIRE) — Grupo Aeroportuario del Pacífico, S.A.B. de C.V. (NYSE: PAC; BMV: GAP) (the “Company” or “GAP”) announces that it has initiated the process for the potential establishment of an Irrevocable Trust for the Issuance of Energy and Infrastructure Investment Trust Certificates (“FIBRA GAP”), with the objective of subscribing a minority equity interest in the 12 Mexican airport concessionaires operated by GAP. Through the initial issuance of FIBRA GAP, each of the 12 airports intends to obtain funds to complement the execution of the Master Development Program for the 2026–2029 period, which contemplates investments of approximately Ps. 40.0 billion. The Master Development Program will generate significant growth in airport infrastructure, including an approximate increase of 60% in...

WUHU, China, May 08, 2026 (GLOBE NEWSWIRE) — During the 2026 International Business Summit, Chery Group’s LEPAS L6 PHEV Global Journey of Elegant Driving successfully completed its comprehensive test drive across China. As a key validation stage within LEPAS’s three-step strategy—“debut, validation, and co-creation”—the journey began at Auto China 2026, regrouped in Wuxi, and concluded at the LEPAS Global Partner Conference in Wuhu. Covering diverse road conditions and real-world scenarios, it showcased the model’s overall strength while reinforcing the brand vision of “Elegance Moves the World.” Throughout the journey, participants explored how a globally oriented NEV brand can redefine mobility aesthetics through elegant technology. The first stop, Wuxi, provided a setting where traditional Chinese elegance meets European...

May 8, 2026 WOBURN, Mass., May 08, 2026 (GLOBE NEWSWIRE) — iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it has priced a private placement with accredited investors for aggregate gross proceeds of approximately $2.5 million, before deducting fees to the placement agent and other offering expenses payable by the Company. In connection with the offering, the Company will issue 488,281 shares of common stock (the “Shares”) at a purchase price of $5.12 per Share. In lieu of Shares that would otherwise result in a purchaser’s beneficial ownership exceeding 4.99% of the outstanding common stock, certain purchasers may elect to receive pre-funded warrants...

Melbourne, Australia, May 08, 2026 (GLOBE NEWSWIRE) — HIGHLIGHTSAmplia and ANZGOG enter into agreement to conduct a clinical study in ovarian cancer evaluating narmafotinib in combination with standard-of-care chemotherapy Ovarian cancer represents a major target for FAK inhibition therapy based on typically higher levels of FAK expression and fibrous nature of tumour The study to enrol patients with high-grade serous ovarian cancer (HGSOC) who have not responded to platinum-based chemotherapy prior to surgery Study focus is safety and exploring potential to improve post-surgical outcomes; biomarker collection will further characterize mechanism of action of narmafotinib{{DATELINECITY_DATE_GLOBENEWSWIRE_BUG}Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), and the Australia New Zealand Gynaecological...

ROCKAWAY, N.J., May 08, 2026 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will be participating in the LD Micro Invitational XVI Conference being held at the Luxe Sunset Boulevard hotel in Los Angeles, CA.   Joshua Lev, Interim President and CFO, will deliver a presentation and host one-on-one meetings throughout the day.   LD Micro Invitational XVI Conference Details: Date: Monday, May 18, 2026 Company Presentation: 10:30 am PT Location: Luxe Sunset Boulevard Hotel, Los Angeles, CA Webcast:   Click for Link For more information or to attend the conference, click here. About electroCore, Inc.electroCore, Inc. is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic...